Karyopharm Therapeutics Inc. (KPTI) Stock Analysis & Investment Frameworks
Karyopharm Therapeutics Inc. (KPTI) stock analysis on Invetso. Review Karyopharm Therapeutics Inc.’s key financial metrics, company overview and 10 institutional-grade investment frameworks including SWOT Analysis, Economic Moat, Porter’s Five Forces and the Invetso Quality Score.
Karyopharm Therapeutics Inc. Company Overview
- Exchange: NASDAQ Global Select
- Sector: Healthcare
- Industry: Biotechnology
- Country: US
Karyopharm Therapeutics Inc. Key Financial Metrics
- Market Cap: $9.63M
- Revenue: $146.07M
- ROE: 77.63%
- ROIC: 376.87%
- Dividend Yield: N/A
About Karyopharm Therapeutics Inc.
Karyopharm Therapeutics Inc. is a pharmaceutical company that has already brought products to market, focusing on identifying, advancing, and selling medications designed to disrupt nuclear export pathways. These drugs are primarily aimed at treating cancer and various other illnesses. The company's strategy involves researching, creating, and marketing innovative Selective Inhibitor of Nuclear Export (SINE) compounds, which operate by attaching to and deactivating the nuclear export protein XPO1. Their leading therapeutic, XPOVIO, holds approvals for several critical applications in adult patients: it is prescribed in combination with bortezomib and dexamethasone for multiple myeloma; alongside dexamethasone for those with heavily pretreated multiple myeloma; and as a standalone treatment for relapsed or refractory diffuse large B-cell lymphoma. Karyopharm has also established a licensing partnership with the Menarini Group, granting them rights to develop and market NEXPOVIO for human oncology indications across Europe (including the United Kingdom), Latin America, and other global regions. Furthermore, the company's oral SINE compounds are specifically engineered to promote the accumulation of various tumor suppressor and growth-regulating proteins within the cell nucleus. Established in 2008, Karyopharm Therapeutics Inc. maintains its principal offices in Newton, Massachusetts.
Karyopharm Therapeutics Inc. Investment Frameworks
Invetso analyzes Karyopharm Therapeutics Inc. (KPTI) across the following frameworks:
- Karyopharm Therapeutics Inc. 10Y Growth Potential
- Karyopharm Therapeutics Inc. Scenario Analysis
- Karyopharm Therapeutics Inc. Risks & Opportunities
- Karyopharm Therapeutics Inc. Economic Moat
- Karyopharm Therapeutics Inc. Business Model
- Karyopharm Therapeutics Inc. Management
- Karyopharm Therapeutics Inc. SWOT Analysis
- Karyopharm Therapeutics Inc. Porter's 5 Forces
- Karyopharm Therapeutics Inc. PESTLE Analysis
- Karyopharm Therapeutics Inc. ESG Analysis